NCT02947711View on ClinicalTrials.gov

Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

January 31, 2017

Conditions

Healthy Subjects

Interventions

DRUG

E2027

2 x 50 mg capsules, once daily on Day 1 and Day 12

DRUG

Diltiazem ER

1 x 300 mg capsule, once daily on Days 7 through 24

Trial Locations (1)

Unknown

San Antonio

All Listed Sponsors

lead

Eisai Co., Ltd.

INDUSTRY

NCT02947711 - Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects | Biotech Hunter | Biotech Hunter